Fatality and adverse event rates of prostaglandin E in treating acute liver failure: a meta- analysis

Chen XiaoHong; Wu ZongYing; Wang YiPing; Ceng Chao; Pan Tao

doi:10.3969/j.issn.1001-5256.2013.09.012

Issue 9

Sep. 2013

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2013 > 29(9): 681-684

PDF( 1247 KB)

Fatality and adverse event rates of prostaglandin E in treating acute liver failure: a meta- analysis

DOI: 10.3969/j.issn.1001-5256.2013.09.012

Department of Gastroenterology, West China Hospital of Sichuan University

Research funding:

Received Date: 2012-12-18
Published Date: 2013-09-20

Abstract

Abstract

Objective To evaluate the fatality and adverse event rates of prostaglandin E ( PGE) versus placebo in treating acute liver failure ( ALF) . Methods A search was performed using Cochrane Library, MEDLINE, EMBASE, VIP, CNKI, CBM, and other electronic databases to select randomized controlled trials ( RCTs) for comparing PGE and placebo in treating ALP published up to April 2012. There were no limits to language and publication. Data extraction and quality evaluation were performed independently by two researchers for the RCTs meeting inclusion criteria; a meta- analysis was performed with RevMan 5. 1 software, and the GRADE system was used to grade the quality of evidence and strength of recommendation. Results Two RCTs involving 59 cases met the inclusion criteria. Compared with the placebo, PGE could not reduce the fatality rate ( RR = 0. 99; 95% CI: 0. 62- 1. 57; P = 0. 96) , as demonstrated by the meta- analysis.Both interventions caused slightly adverse events, but no incidence rate was reported. Based on the GRADE system, the quality of evidence was low ( 2C) , and the strength of recommendation was weak. Conclusion PGE cannot reduce the fatality of ALF, according to the systematic review. Large- scale, high- quality basic and clinical researches should be performed to confirm the conclusion because the systematic review is secondary study, the literature included has low quality of evidence, and there may be bias in review.
- live failure, acute,
- prostaglandins E,
- Meta-analysis

FullText(HTML)

References(35)

References

[1]GILL RQ, STERLING RK.Acute liver failure[J].J Clin Gastroenterol, 2001, 33 (3) :191-198.

[2]HOOFNAGLE JH, CARITHERS RL Jr, SHAPIRO C, et al.Fulminant hepatic failure:summary of a workshop[J].Hepatology, 1995, 21 (1) :240-252.

[3]SEABERG EC, BELLE SH, BERINGER KC, et al.Liver transplantation in the United States from 1987-1998:updated results from the Pitt-UNOS Liver Transplant Registry[J].Clin Transpl, 1998:17-37.

[4]CAPOCACCIA L, ANGELICO M.Fulminant hepatic failure.Clinical features, etiology, epidemiology, and current management[J].Dig Dis Sci, 1991, 36 (6) :775-779.

[5]FINGEROTE RJ, BAIN VG.Fulminant hepatic failure[J].Am J Gastroenterol, 1993, 88 (7) :1000-1010.

[6]LEE WM.Acute liver failure[J].Am J Med, 1994, 96 (1A) :3s-9s.

[7]MUNOZ SJ.Difficult management problems in fulminant hepatic failure[J].Semin Liver Dis, 1993, 13 (4) :395-413.

[8]SHERLOCK S.Fulminant hepatic failure[J].Adv Intern Med, 1993, 38:245-267.

[9]SINCLAIR S, WAKEFIELD A, LEVY G.Fulminant hepatitis[J].Springer Semin Immunopathol, 1990, 12 (1) :33-45.

[10]WIESNER RH.Acute fulminant hepatic failure[J].Transplant Proc, 1991, 23 (3) :1892-1894.

[11]Randomised trial of steroid therapy in acute liver failure.Report from the European Association for the Study of the Liver (EASL) [J].Gut, 1979, 20 (7) :620-623.

[12]RAKELA J, MOSLEY JW, EDWARDS VM, et al.A doubleblinded, randomized trial of hydrocortisone in acute hepatic failure.The Acute Hepatic Failure Study Group[J].Dig Dis Sci, 1991, 36 (9) :1223-1228.

[13]WOOLF GM, REDEKER AG.Treatment of fulminant hepatic failure with insulin and glucagon.A randomized, controlled trial[J].Dig Dis Sci, 1991, 36 (1) :92-96.

[14]HUGHES R, WWILLIAMS R.Clinical experience with charcoal and resin hemoperfusion[J].Semin Liver Dis, 1986, 6 (2) :164-173.

[15]O'GRADY J, GIMSON A, O'BRIEN C, et al.Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure[J].Gastroenterology, 1988, 94 (5 Pt 1) :1186.

[16]ASCHER NL, LAKE JR, EMOND JC, et al.Liver transplantation for fulminant hepatic failure[J].Arch Surg, 1993, 128 (6) :677-682.

[17]STIEBER AC, IWATSUKI S, STARZL TE.Orthotopic liver transplantation for fulminant and subacute hepatic failure[J].ASAIO Trans, 1988, 34 (4) :959-964.

[18]TAKAHASHI Y, KUMADA H, SHIMIZU M, et al.A multicenter study on the prognosis of fulminant viral hepatitis:early prediction for liver transplantation[J].Hepatology, 1994, 19 (5) :1065-1071.

[19]ABECASSIS M, FALK JA, MAKOWKA L, et al.16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection[J].J Clin Invest, 1987, 80 (3) :881-889.

[20]ADACHI N, OCHI T, TABO E, et al.Prostaglandin E1 improves hepatic encephalopathy produced by ischaemia-reperfusion liver injury in rats[J].Intensive Care Med, 2000, 26 (11) :1681-1684.

[21]MONTO GL, SCHEUER PJ, HANSING RL, et al.Attenuation of acetaminophen hepatitis by prostaglandin E2.A histopathological study[J].Dig Dis Sci, 1994, 39 (5) :957-960.

[22]MUNTANE J, MONTERO JL, MARCHAL T, et al.Effect of PGE1on TNF-alpha status and hepatic D-galactosamine-induced apoptosis in rats[J].J Gastroenterol Hepatol, 1998, 13 (2) :197-207.

[23]MUNTANE J, RODRIGUEZ FJ, SEGADO O, et al.TNF-alpha dependent production of inducible nitric oxide is involved in PGE (1) protection against acute liver injury[J].Gut, 2000, 47 (4) :553-562.

[24]QUIROGA J, PRIETO J.Liver cytoprotection by prostaglandins[J].Pharmacol Ther, 1993, 58 (1) :67-91.

[25]RUWART MJ, RUSH BD, FRIEDLE NM, et al.Protective effects of 16, 16-dimethyl PGE2 on the liver and kidney[J].Prostaglandins, 1981, 21 (Suppl) :97-102.

[26]SINCLAIR S, LEVY G.Eicosanoids and the liver[J].Ital J Gastroenterol, 1990, 22 (4) :205-213.

[27]O'BRIEN C, HENZEL B, NAJI A, et al.Prostaglandin E1 infusions improve survival of patients with fulminant hepatic failure[J].Gastroenterology, 1992, 102:a862.

[28]SINVLSIT SB, GREIG PD, BLENDIS LM, et al.Biochemical and clinical response of fulminant viral hepatitis to administration of prostaglandin E.A preliminary report[J].J Clin Invest 1989, 84 (4) :1063-1069.

[29]SINCLAIR SB, LEVY GA.Treatment of fulminant viral hepatic failure with prostaglandin E.A preliminary report[J].Dig Dis Sci, 1991, 36 (6) :791-800.

[30] BERNAUA J, BABANY G, BEZEAUD A.Does prostaglandin E1prevent further aggravation in severe or early fulminant hepatitis?A preliminary open trial[abstract][J].J Hepatol, 1989, 9:s114.

[31] International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use[J].Int Dig Health Legis, 1997, 48 (2) :231-234.

[32]HIGGINS JPT, GREEN S.Cochrane handbook for systematic reviews of interventions 4.2.4[updated March 2005].The Cochrane Library, (2) , 2005.

[33]SHEINER P, SINCLAIR S, GREIG P, et al.A randomized controlled trial of prostaglandin E 2 (PGE 2) in the treatment of fulminant hepatic failure (FHF) [abstract][J].Hepatology, 1992, 16:88-88.

[34]STERLING RK, LUKETIC VA, SANYAL AJ, et al.Treatment of fulminant hepatic failure with intravenous prostaglandin E1[J].Liver Transpl Surg, 1998, 4 (5) :424-431.

[35]ZHANG Q, SUN FX.Clinical study on acute, subacute liver failure[J/CD].Chin J Exp Clin Infect Dis (Electronic Edition) , 2012, 6 (2) :165-167. (in Chinese) 张强, 孙凤霞.急性、亚急性肝衰竭临床研究进展[J/CD].中华实验和临床感染病杂志 (电子版) , 2012, 6 (2) :165-167.

Relative Articles

[1]	Decai KONG, Xiaojing ZHANG, Yangguang YUN, Haoyu DUAN, Junfeng YE. Risk factors for biliary stricture and prognosis after orthotopic liver transplantation[J]. Journal of Clinical Hepatology, 2024, 40(11): 2253-2259. doi: 10.12449/JCH241119
[2]	Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019
[3]	Wanshu LIU, Lijun SHEN, Qinghui ZHAI, Shaojie XIN, Shaoli YOU. Risk factors for acute variceal bleeding in acute-on-chronic liver failure and its influence on prognosis[J]. Journal of Clinical Hepatology, 2022, 38(11): 2532-2536. doi: 10.3969/j.issn.1001-5256.2022.11.018
[4]	Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020
[5]	Ping ZHU, Heping ZHAO, Tao HAN, Qing YE, Tinghong LI, Huiling XIANG. Evaluation and influencing factors of the short-term prognosis of severe alcoholic hepatitis with different underlying liver diseases[J]. Journal of Clinical Hepatology, 2021, 37(2): 370-374. doi: 10.3969/j.issn.1001-5256.2021.02.024
[6]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[7]	Li Ying, Zhan Jing, Wang ZhongFeng. Prognostic factors for patients with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2017, 33(3): 497-501. doi: 10.3969/j.issn.1001-5256.2017.03.020
[8]	Wang FengJiao, Liu MingJiang, Wu RuiHong, Niu JunQi. A multivariate logistic regression analysis of short-term prognosis of patients with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2017, 33(4): 711-714. doi: 10.3969/j.issn.1001-5256.2017.04.022
[9]	Cui YanPing, Li QingFang, Li QingYan, Liu ChunHua, Wang WeiHong, Yuan JianGuo, Wang SiKui. Logistic regression analysis of prognostic risk factors for hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2016, 32(1): 135-138. doi: 10.3969/j.issn.1001-5256.2016.01.026
[10]	Shi XinXing, Zhang YanQiong, Zhu Peng, Yan GuoHua, Zhang ZhangJiang, Wang YuMing. Prognostic risk factors in patients with hepatitis B virus- related acute- on- chronic liver failure[J]. Journal of Clinical Hepatology, 2016, 32(4): 700-705. doi: 10.3969/j.issn.1001-5256.2016.04.018
[11]	Qiao LiNa, Dai GuangRong, Zhang Jin, Shen Ni. An epidemiological survey of prevalence and risk factors for fatty liver disease in adults residing in Yan'an,China[J]. Journal of Clinical Hepatology, 2015, 31(1): 82-87. doi: 10.3969/j.issn.1001-5256.2015.01.018
[12]	Chen YongFang, Wu ZhanJun. Pathogenesis and risk factors of cholesterol gallstones in patients with non- alcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 952-955. doi: 10.3969/j.issn.1001-5256.2013.12.021
[13]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[14]	Zhang DongQing, Chen Li, Gan QiaoRong, Zhou Rui, Huang JianRong, Pan Chen. Prognostic factors for hepatitis B acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2012, 28(10): 740-743.
[15]	Liu HongHong, Fu JunLiang, Fu BaoYun, Zhang Zheng, Xu RuoNan, Luo ShengQiang, Shi Ming, Li YongGang, Wang FuSheng. The pathogenesis and risk factors related to prognosis of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(2): 153-155.
[16]	Lu: RiYing, Li ShiXiong, Wu JiZhou, Zhu YuJia, Fu ShaoPing. Development of a prognostic factors model for severe hepatitis[J]. Journal of Clinical Hepatology, 2012, 28(10): 789-792.
[17]	Zhang YiNing, Du HongWei, Liu YanJun, Wang ChaoXia. The diagnosis and risk factors for evaluation of nonalcoholic fatty liver disease in children and adolescents[J]. Journal of Clinical Hepatology, 2011, 27(7): 690-693.
[18]	Liu XiaoYan, Li ShengMian, Yang Jian. The incidence and prognosis of non-alcoholic fatty liver disease in primary liver cancer 1293 cases[J]. Journal of Clinical Hepatology, 2010, 26(6): 641-643.
[19]	Chen MingWei, Yang MingGong, Wang YouMin, Wang ZhangJiang, Pan TianRong, Hu HongLin, Sun HaiYan. Risk factors analysis on nonalcoholic steatohepatitis in patients with type 2 diabetes[J]. Journal of Clinical Hepatology, 2004, 20(1): 44-45.
[20]	Ding HuiGuo, Gao GuiJu, Chen Tao, Jin Rui. Prognosis of Severe Types of Virous Hepatitis: Study on Mutiple Risk Factors.[J]. Journal of Clinical Hepatology, 2002, 18(5): 297-299.

Supplements(0)

Cited By

Cited by

Periodical cited type(4)

1.	王静，王佳琪，陈芳，夏杰，李露锋，毛青. ALT正常的慢性乙型肝炎患者抗病毒治疗疗效和安全性的真实世界研究. 重庆医学. 2025(01): 138-141 .
2.	何雄志. 红外肝病治疗仪联合富马酸丙酚替诺福韦治疗慢性乙型肝炎的临床效果. 中外医学研究. 2025(06): 36-39 .
3.	唐海涛，王娴，周佳琦，王凤梅，张文华. 富马酸丙酚替诺福韦治疗初治失代偿期乙型肝炎肝硬化患者的临床研究. 肝脏. 2024(07): 830-833 .
4.	付文鹏，慕少英. 富马酸丙酚替诺福韦治疗慢性乙型病毒性肝炎的临床疗效分析. 系统医学. 2024(23): 39-42 .

Other cited types(2)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3349) PDF downloads(718)

Fatality and adverse event rates of prostaglandin E in treating acute liver failure: a meta- analysis

DOI: 10.3969/j.issn.1001-5256.2013.09.012